Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Kerry has opened up about her daughter Lilly-Sue surprising her with a visit recently - her second eldest daughter moved to ...

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

Purdue Global, with support from the Lilly Foundation, is introducing a new initiative to assist paraeducators in Marion County to become licensed math teachers by working with MathTrack Institute.

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

The football legend, 44, has revealed another huge milestone for his family, announcing that his youngest son has taken part ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.